Summary of Use during Lactation

No information is available on the clinical use of amivantamab during breastfeeding. Because amivantamab is a large protein molecule with a molecular weight of 148,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. The manufacturer recommends avoiding breastfeeding during amivantamab use and for 3 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

amivantamab

CAS Registry Number

2171511-58-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents, Immunological

Antibodies, Bispecific

Antibodies, Monoclonal